This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Carl Walkey Biography and Net Worth

SVP of Neoleukin Therapeutics

Carl brings scientific, product, and business development experience spanning multiple industries. Prior to joining Neoleukin Therapeutics, he served as a Senior Fellow at the Institute for Protein Design, where he led projects focused on the application of computational protein design to address unmet needs in oncology and autoimmunity. In 2014, he co-founded Ansible Marketing, which develops machine learning tools to automate omni-channel communications for small and medium businesses. Over the past decade, Dr. Walkey has co-authored over a dozen research works and received numerous prestigious scholarships and awards, including the Alexander Graham Bell Canada Graduate Scholarship and NSERC Postdoctoral Fellowship. Dr. Walkey received his PhD from the University of Toronto, where he applied machine learning to develop enhanced nanomedicines for drug delivery and vaccine development.

What is Carl Walkey's net worth?: The estimated net worth of Carl Walkey is at least $2.11 million as of June 16th, 2021. Dr. Walkey owns 67,624 shares of Neoleukin Therapeutics stock worth more than $2,107,840 as of April 24th. This net worth evaluation does not reflect any other investments that Dr. Walkey may own. Learn More about Carl Walkey's net worth.
How do I contact Carl Walkey?: The corporate mailing address for Dr. Walkey and other Neoleukin Therapeutics executives is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. Neoleukin Therapeutics can also be reached via phone at (866) 245-0312 and via email at [email protected]. Learn More on Carl Walkey's contact information.
Has Carl Walkey been buying or selling shares of Neoleukin Therapeutics?: Carl Walkey has not been actively trading shares of Neoleukin Therapeutics during the past quarter. Most recently, Carl Walkey sold 30 shares of the business's stock in a transaction on Wednesday, June 16th. The shares were sold at an average price of $203.80, for a transaction totalling $6,114.00. Following the completion of the sale, the senior vice president now directly owns 67,624 shares of the company's stock, valued at $13,781,771.20. Learn More on Carl Walkey's trading history.
Who are Neoleukin Therapeutics' active insiders?: Neoleukin Therapeutics' insider roster includes Jonathan Drachman (CEO), and Carl Walkey (SVP). Learn More on Neoleukin Therapeutics' active insiders.
Are insiders buying or selling shares of Neoleukin Therapeutics?: During the last year, Neoleukin Therapeutics insiders bought shares 2 times. They purchased a total of 102,787 shares worth more than $1,305,132.60. During the last year, insiders at the sold shares 1 times. They sold a total of 66 shares worth more than $818.40. The most recent insider tranaction occured on August, 17th when Director Bros. Advisors Lp Baker bought 8,347 shares worth more than $115,188.60. Insiders at Neoleukin Therapeutics own 1.6% of the company. Learn More about insider trades at Neoleukin Therapeutics.
Information on this page was last updated on 8/17/2023.

Carl Walkey Insider Trading History at Neoleukin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/16/2021	Sell	30	$203.80	$6,114.00	67,624
6/8/2021	Sell	30	$220.00	$6,600.00	67,686
6/4/2021	Sell	30	$200.00	$6,000.00	67,716
5/26/2021	Sell	30	$200.00	$6,000.00	67,746
5/19/2021	Sell	30	$212.60	$6,378.00
5/12/2021	Sell	60	$221.80	$13,308.00	67,738
5/5/2021	Sell	60	$226.00	$13,560.00	67,798
4/28/2021	Sell	120	$251.60	$30,192.00	67,858
4/26/2021	Sell	30	$260.00	$7,800.00	67,978
4/21/2021	Sell	90	$239.60	$21,564.00	68,008
4/14/2021	Sell	90	$244.40	$21,996.00	68,098
4/7/2021	Sell	90	$240.40	$21,636.00	68,188
4/5/2021	Sell	30	$260.00	$7,800.00	68,278
3/31/2021	Sell	90	$239.20	$21,528.00	68,308
3/24/2021	Sell	90	$239.00	$21,510.00	68,488
3/22/2021	Sell	30	$240.00	$7,200.00	68,488
3/17/2021	Sell	60	$227.20	$13,632.00	68,518
3/10/2021	Sell	90	$239.40	$21,546.00
3/3/2021	Sell	90	$237.40	$21,366.00	68,668
2/24/2021	Sell	90	$242.80	$21,852.00	68,788
2/3/2021	Sell	120	$264.60	$31,752.00	69,178

Carl Walkey Buying and Selling Activity at Neoleukin Therapeutics

Neoleukin Therapeutics Company Overview

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Today's Range

Now: $31.17

$30.70

$33.08

50 Day Range

MA: $37.21

$13.96

$50.90

2 Week Range

Now: $31.17

$2.03

$14.36

Volume

58,205 shs

Average Volume

50,104 shs

Market Capitalization

$292.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11